CRST and Kancera AB signed a contract for a First-in-human trial with KAND145 CRST and Kancera AB entered into a contract for a First-in-human trial of KAND145, Kancera’s second generation fractalkine blocking drug candidate, primarily intended for cancer indications. Kancera…
CRST has appointed Petri Vainio as the CRST’s new Chief Scientific Officer CRTS is pleased to announce that company has appointed MD, PhD, Adjunct Professor of Pharmacology and Drug development Petri Vainio as the CRST’s new Chief Scientific Officer starting…
CRST’s scientific team contributed in a study evaluating an ASO in mild Alzheimer’s disease A recently published phase Ib study in the journal Nature Medicine reported that intrathecal administration of a Tau-targeting antisense oligonucleotides (ASO), MAPTRx, resulted in sustained reduction…
CRST toteuttaa kliinisiä lääketutkimuksia lukuisilla eri indikaatioalueilla: tutkittavien lääkevalmisteiden kohdesairaudet vaihtelevat esimerkiksi sydäninfarktista keliakiaan ja Alzheimerin tautiin. Yhtenä tärkeimmistä uusista kasvualueista on lihavuuden hoitoon käytettävien lääkkeiden kliiniset tutkimukset. Lihavuuden hoidon asiantuntija, ylilääkäri André Heikius kertoo lihavuuden hoidossa nykyisin käytettävistä lääkkeistä.…
Reaching the next level A key account management (KAM) is the process of planning and managing a mutually beneficial partnership between a company and its most important clients. These clients are significant to company’s sustainable, long-term growth.As one of the elements…